FocalTherics (NASDAQ:FOCL) Raised to “Strong-Buy” at Mizuho

FocalTherics (NASDAQ:FOCL) was upgraded by Mizuho to a “strong-buy” rating in a note issued to investors on Friday,Zacks.com reports.

Several other research analysts also recently commented on FOCL. Wall Street Zen downgraded FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $9.00.

FocalTherics Stock Performance

NASDAQ FOCL opened at $5.43 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79. The stock has a market cap of $203.52 million, a price-to-earnings ratio of -6.70 and a beta of -0.04. FocalTherics has a 12-month low of $1.21 and a 12-month high of $5.64.

FocalTherics (NASDAQ:FOCL) last issued its earnings results on Thursday, May 7th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $20.48 million during the quarter, compared to the consensus estimate of $19.46 million. FocalTherics had a negative return on equity of 137.61% and a negative net margin of 41.47%. Sell-side analysts expect that FocalTherics will post -0.78 EPS for the current year.

Insiders Place Their Bets

In other FocalTherics news, Director Joshua Levine purchased 10,000 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $4.22 per share, for a total transaction of $42,200.00. Following the completion of the purchase, the director owned 35,000 shares of the company’s stock, valued at approximately $147,700. The trade was a 40.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.10% of the company’s stock.

Hedge Funds Weigh In On FocalTherics

Several hedge funds have recently made changes to their positions in the company. Flax Pond Capital LLC acquired a new position in FocalTherics during the 4th quarter valued at approximately $2,623,000. Leonteq Securities AG bought a new stake in FocalTherics in the fourth quarter valued at $313,000. Rock Springs Capital Management LP boosted its holdings in shares of FocalTherics by 7.1% during the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after acquiring an additional 91,500 shares during the period. Kovack Advisors Inc. acquired a new position in shares of FocalTherics during the fourth quarter valued at $53,000. Finally, Lido Advisors LLC bought a new position in shares of FocalTherics during the first quarter worth about $40,000. 62.74% of the stock is owned by institutional investors and hedge funds.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.